Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Sexually Transmitted Infections01:26

Sexually Transmitted Infections

175
Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
175

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Nasal and Ocular Immunization with Bacteriophage Virus-like Particle Vaccines Elicits Distinct Systemic and Mucosal Antibody Profiles.

Vaccines·2025
Same author

Immunization Against <i>Chlamydia trachomatis</i> Polymorphic Membrane Protein D Tetrapeptide Motifs Limits Early Female Reproductive Tract Infection in a Mouse Model.

Vaccines·2025
Same author

Two doses of Qβ virus like particle vaccines elicit protective antibodies against heroin and fentanyl.

NPJ vaccines·2025
Same author

Pathogenic and Protective Roles of Neutrophils in <i>Chlamydia trachomatis</i> Infection.

Pathogens (Basel, Switzerland)·2025
Same author

Web Exclusive. Annals On Call - Kratom: A Substance Physicians Should Be Aware Of.

Annals of internal medicine·2024
Same author

A two-dose regimen of Qβ virus-like particle-based vaccines elicit protective antibodies against heroin and fentanyl.

bioRxiv : the preprint server for biology·2024

相关实验视频

Updated: May 7, 2025

Forward Genetic Approaches in Chlamydia trachomatis
09:03

Forward Genetic Approaches in Chlamydia trachomatis

Published on: October 23, 2013

12.8K

针对克拉米迪亚形虫的有效疫苗的进展.

Amanda L Collar1, Kathryn M Frietze2

  • 1Department of Internal Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.

Current opinion in infectious diseases
|January 2, 2025
PubMed
概括
此摘要是机器生成的。

开发一种有效的疫苗来对抗克拉米迪亚螺旋虫 (Ct) 感染正在接近现实. 最近的试验表明,CTH522疫苗具有前景,正在进行的研究正在探索Ct疫苗开发的新方法.

更多相关视频

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development
12:53

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Published on: March 16, 2022

1.6K
Markerless Gene Deletion by Floxed Cassette Allelic Exchange Mutagenesis in Chlamydia trachomatis
10:35

Markerless Gene Deletion by Floxed Cassette Allelic Exchange Mutagenesis in Chlamydia trachomatis

Published on: January 30, 2020

6.6K

相关实验视频

Last Updated: May 7, 2025

Forward Genetic Approaches in Chlamydia trachomatis
09:03

Forward Genetic Approaches in Chlamydia trachomatis

Published on: October 23, 2013

12.8K
Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development
12:53

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Published on: March 16, 2022

1.6K
Markerless Gene Deletion by Floxed Cassette Allelic Exchange Mutagenesis in Chlamydia trachomatis
10:35

Markerless Gene Deletion by Floxed Cassette Allelic Exchange Mutagenesis in Chlamydia trachomatis

Published on: January 30, 2020

6.6K

科学领域:

  • 传染性疾病 传染性疾病
  • 疫苗学 疫苗学 疫苗学
  • 免疫学 免疫学 免疫学

背景情况:

  • 性传播的克拉米迪亚螺旋虫 (Ct) 感染构成了全球重大健康挑战.
  • 对Ct的有效疫苗一直是长期以来的研究目标,迄今为止取得的成功有限.
  • 了解Ct的自然免疫反应对于疫苗设计至关重要.

研究的目的:

  • 审查最近在开发针对Chlamydia trachomatis的疫苗方面的进展.
  • 突出有希望的疫苗候选人和新兴的研究策略.

主要方法:

  • 审查最近的临床试验数据,重点关注CTH522疫苗.
  • 分析临床前研究,探索新型抗原,辅助剂和施用途径.
  • 综合当前对免疫反应对Ct感染的理解.

主要成果:

  • 2019年,第一个在人体中使用的克拉米迪亚形虫疫苗CTH522报告了I/IIB期试验结果.
  • CTH522及其衍生物被确定为主要的疫苗候选物.
  • 临床前开发包括向非MOMP抗原,并利用新的辅助剂和给药途径.

结论:

  • 克拉米迪亚形虫疫苗的批准比之前预期的更近.
  • 仔细考虑实施策略对于成功的Ct疫苗临床转化至关重要.